Phase II Study of Regorafenib as Maintenance Therapy
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib®
to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas
experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as
1st line chemotherapy.